Financial Survey: Ayr Wellness (OTCMKTS:AYRWF) versus ImmuCell (NASDAQ:ICCC)

ImmuCell (NASDAQ:ICCC) and Ayr Wellness (OTCMKTS:AYRWF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Valuation & Earnings

This table compares ImmuCell and Ayr Wellness”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64 million	3.64	-$1.04 million	($0.06)	-185.50
Ayr Wellness	$463.63 million	0.00	-$359.31 million	($1.62)	-0.01

ImmuCell has higher earnings, but lower revenue than Ayr Wellness. ImmuCell is trading at a lower price-to-earnings ratio than Ayr Wellness, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ImmuCell has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Ayr Wellness has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for ImmuCell and Ayr Wellness, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1	0	0	0	1.00
Ayr Wellness	0	0	0	0	0.00

Profitability

This table compares ImmuCell and Ayr Wellness’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Ayr Wellness	N/A	N/A	N/A

Insider and Institutional Ownership

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 0.9% of Ayr Wellness shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by company insiders. Comparatively, 8.1% of Ayr Wellness shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Ayr Wellness beats ImmuCell on 7 of the 12 factors compared between the two stocks.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

About Ayr Wellness

Ayr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.